
## Stéphane Ducassou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1310155/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood, 2019, 134, 9-21.	1.4	102
2	Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort). International Journal of Epidemiology, 2015, 44, 49-57.	1.9	60
3	Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Longâ€ŧerm followâ€up from the French national cohort. Pediatric Blood and Cancer, 2013, 60, 1759-1765.	1.5	35
4	Romiplostim in children with chronic immune thrombocytopenia ( <scp>ITP</scp> ): the <scp>F</scp> rench <scp>E</scp> xperience. British Journal of Haematology, 2014, 164, 266-271.	2.5	31
5	Benefits of rituximab as a secondâ€ŀine treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British Journal of Haematology, 2017, 177, 751-758.	2.5	24
6	Maintenance Therapy With Interleukinâ $€2$ for Childhood AML. HemaSphere, 2018, 2, e159.	2.7	18
7	Genotype/phenotype correlations of childhoodâ€onset congenital sideroblastic anaemia in a European cohort. British Journal of Haematology, 2019, 187, 530-542.	2.5	18
8	Impact of shared care program in followâ€up of childhood cancer survivors: An intervention study. Pediatric Blood and Cancer, 2017, 64, e26541.	1.5	17
9	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Pediatric Blood and Cancer, 2020, 67, e28032.	1.5	17
10	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial. Journal of Clinical Oncology, 2021, 39, 3546-3560.	1.6	17
11	Expression of PDâ€1/PDâ€L1 in children's classical Hodgkin lymphomas. Pediatric Blood and Cancer, 2019, 66, e27571.	1.5	13
12	Secondâ€line treatment trends and longâ€term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25Âyears. British Journal of Haematology, 2020, 189, 931-942.	2.5	12
13	<i>MYB–GATA1</i> fusion promotes basophilic leukaemia: involvement of interleukinâ€33 and nerve growth factor receptors. Journal of Pathology, 2017, 242, 347-357.	4.5	10
14	Singleâ€dose (4.5Âmg/m <sup>2</sup> ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. British Journal of Haematology, 2022, 198, 373-381.	2.5	9
15	Tolerance to arsenic trioxide combined with allâ€transâ€retinoic acid in children with acute promyelocytic leukaemia in France. British Journal of Haematology, 2020, 188, 170-173.	2.5	6
16	Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood, 2022, 140, 253-261.	1.4	6
17	Impact of therapy in a cohort of unselected children with Down Syndromeâ€∎ssociated Acute Lymphoblastic Leukaemia. British Journal of Haematology, 2016, 174, 983-985.	2.5	4
18	Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. Journal of Pediatrics, 2021, 231, 223-230.	1.8	1